Scribe Therapeutics
Filed with the SEC on · accession 0001193125-26-458503
SCTX filed a 10-Q (quarterly report) with the SEC on Nov 12, 2026. Scribe Therapeutics filed its Q3 2026 Form 10-Q, reporting quarterly financial results and disclosing its IPO and private placement completed in July 2026. The stock moved +0.8% by the first close after the filing.
Scribe Therapeutics filed its Q3 2026 Form 10-Q, reporting quarterly financial results and disclosing its IPO and private placement completed in July 2026. The filing includes standard financial statements, license agreements, and equity activity.
Close before
$16.86
Nov 11, 2026
First close after
+0.77%
$16.99
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for SCTX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for SCTX?
Click hereSCTX filed a 10-Q (SEC filing). Scribe Therapeutics filed its Q3 2026 Form 10-Q, reporting quarterly financial results and disclosing its IPO and private placement completed in July 2026. The filing includes standard financial statements, license agreements, and equity activity.
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
SCTX closed at $16.86 before the filing and $16.99 on Nov 12, 2026 (+0.77%).
Get alerts when SCTX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days